The latest data from ENETS 2026 How will new data impact clinical practice? 📈 Expert insights from Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand 📺 Watch for an update on: -Breakthrough results from the COMPETE study with #PRRT in pancreatic #NETS before targeted therapy -Strategies for re-challenge with PRRT -Positive data from the DAREONᵀᴹ-7 trial of obrixtamig, a DLL3-targeted bi-specific T cell engager, as 1st line therapy for advanced NEC -The role of surgery in stage 1–3 disease -The interesting combination treatment of cabozantinib and temozolomide for NETs Get the key clinical takeaways: cor2ed.com/net-connect/progr… This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community. #MedEd #OncTwitter #NETs #NeuroendocrineTumors #NeuroendocrineCancer #NETCancer #ENETS2026

Update from #ENETS2026 📺 Get key takeaways from the congress, including: 🔎 Results of the COMPETE trial subgroup analysis comparing PRRT and everolimus 🔎 What the latest data from the DAREONᵀᴹ-7 trial reveal about obrixtamig, a DLL3 bi-specific T cell engager 🔎 The role of surgical resection in stage 1–3 NECs 🔎Strategies for re-challenging PRRT in NET patients 🔎 The interesting combination treatment of cabozantinib and temozolomide for NETs From Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand See more! >> cor2ed.com/net-connect/progr… This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community. #MedEd #OncTwitter #NETs #NeuroendocrineTumors #NeuroendocrineCancer #NETCancer

This month during ENETS 2026 we were delighted to bring together a new group of highly engaged early-career researchers from across Europe, representing a range of specialties. With the guidance of an experienced Scientific Committee, they began shaping collaborative projects in #NENs to advance knowledge and share insights across the field. A sincere thank you to everyone involved, we look forward to seeing these projects develop and to the collaborations ahead.

📣 Update from #ENETS2026 Experts share their views on the latest practice-changing data in #neuroendocrinecancer 📺 From Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand The experts discuss: ➡️ Breakthrough results presented from the COMPETE study ➡️ Positive data from the DAREONᵀᴹ-7 trial ➡️ The interesting combination treatment of cabozantinib and temozolomide for NETs …and more! See the rest of this programme & get the key clinical takeaways: cor2ed.com/net-connect/progr… This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community. #MedEd #OncTwitter #NETs #NeuroendocrineTumors #NETCancer

📺 Highlights from #ENETS2026 Discover the latest clinical practice changing insights from the conference in Krakow, Poland. Experts Prof. Louis de Mestier, Prof. @TimonV and Dr Alice Durand share insights into new data on PRRT in treatment sequencing and re-challenge in NETs, obrixtamig as 1st line therapy in advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss interesting combination treatment. How will new data impact clinical practice? Watch the video below to find out. This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community. #MedEd #NeuroendocrineTumors #NeuroendocrineCancer #NETs #NETCancer